title: [Specific aspects and care of lung involvement in adults with cystic fibrosis].
abstract: Respiratory impairment is present in almost all adult cystic fibrosis patients and makes the prognosis. Viscous, infected and abundant secretions, inflammation and bronchial oedema, bronchoconstriction and respiratory muscle fatigue lead to airway obstruction, bronchiectasis and respiratory failure. The disease is preferentially located in the upper lobes. Exacerbations of the disease are due to bronchial infections and are often responsible for drops of the respiratory function. Regular spirometric surveillance is fundamental for the prognosis and the assessment of the effects of the treatment. Among adult patients chronic colonisation with mucoid and often multiresistant strains of Pseudomonas Aeruginosa are common. It is treated with i.v. high doses antibiotic courses and nebulized antibiotics between i.v. courses. Respiratory failure may require long term oxygen and non invasive mechanical ventilation. Systemic hypervascularization around the bronchiectasis may lead to moderate to severe hemoptysis, which may require embolization. Pneumothorax are associated with poor prognosis and are treated by pleural drainage and if failure by thoracoscopy.
authors.affiliation: Service de Pneumologie, CHU, Grenoble. IPin@chu-grenoble.fr
authors.forename: I
authors.initials: I
authors.lastname: Pin
authors.forename: D
authors.initials: D
authors.lastname: Grenet
authors.forename: P
authors.initials: P
authors.lastname: Scheid
authors.forename: P
authors.initials: P
authors.lastname: Domblides
authors.forename: M
authors.initials: M
authors.lastname: Stern
authors.forename: D
authors.initials: D
authors.lastname: Hubert
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001987:Bronchiectasis / Q000209:etiology* / Q000628:therapy; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D006469:Hemoptysis / Q000209:etiology / Q000628:therapy; D006801:Humans; D016040:Lung Transplantation; D010102:Oxygen Inhalation Therapy; D011014:Pneumonia / Q000209:etiology* / Q000628:therapy; D013902:Radiography, Thoracic; D012121:Respiration, Artificial; D012129:Respiratory Function Tests; D012131:Respiratory Insufficiency / Q000209:etiology* / Q000628:therapy; D012138:Respiratory Therapy; D014057:Tomography, X-Ray Computed
chemical_list: D000305:Adrenal Cortex Hormones; D000336:Aerosols; D000900:Anti-Bacterial Agents; D001993:Bronchodilator Agents